US2018177727A1PendingUtilityA1

Use of exosomes for the treatment of disease

50
Assignee: UNIV TEXASPriority: Jun 10, 2015Filed: Jun 10, 2016Published: Jun 28, 2018
Est. expiryJun 10, 2035(~8.9 yrs left)· nominal 20-yr term from priority
Inventors:Raghu KalluriSónia Melo
A61K 45/06A61P 35/00C12N 2310/14A61K 9/1271A61K 9/0019C12N 15/1135A61K 31/7088A61K 47/46A23V 2002/00A23L 33/40A23L 33/185A23L 29/269A23L 29/262A23L 29/256A23L 29/25A23L 29/238A23L 29/231A23L 29/212A23L 29/20A23L 27/60A23L 25/10A23L 23/10A23L 9/10A23C 19/0904A61K 9/5068A61K 9/127C12N 15/88C12N 15/113A61K 47/42A61K 39/395A61K 48/00A61K 49/0084
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides lipid-based nanoparticles (e.g., liposomes or exosomes) having CD47 on their surface and comprising a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug). Furthermore, the present invention provides for use of such lipid-based nanoparticles in therapy.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising a lipid-based nanoparticle and an excipient, wherein the lipid-based nanoparticle comprises CD47 on its surface and wherein the lipid-based nanoparticle comprises a therapeutic agent. 
     
     
         2 . The composition of  claim 1 , wherein the lipid-based nanoparticle is a liposome or an exosomes. 
     
     
         3 . The composition of  claim 2 , wherein the exosomes is isolated from a cell over expressing CD47. 
     
     
         4 . The composition of  claim 2 , wherein the exosomes is isolated from a fibroblast cell. 
     
     
         5 . The composition of  claim 2 , wherein the liposome is a single lamellar liposome. 
     
     
         6 . The composition of  claim 2 , wherein the liposome is a multilamellar liposome. 
     
     
         7 . The composition of  claim 1 , wherein the therapeutic agent is a therapeutic protein, an antibody, an inhibitory RNA, or a small molecule drug. 
     
     
         8 . The composition of  claim 7 , wherein the antibody binds an intracellular antigen. 
     
     
         9 . The composition of  claim 7 , wherein the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody. 
     
     
         10 . The composition of  claim 7 , wherein the inhibitory RNA is a siRNA, shRNA, miRNA, or pre-miRNA. 
     
     
         11 . The composition of  claim 7 , wherein the therapeutic protein is a kinase, a phosphatase, or a transcription factor. 
     
     
         12 . The composition of  claim 7 , wherein the small molecule drug is an imaging agent. 
     
     
         13 . The composition of  claim 1 , wherein the composition is formulated for parenteral administration. 
     
     
         14 . The composition of  claim 13 , wherein the composition is formulated for intravenous, intramuscular, sub-cutaneous, or intraperitoneal injection. 
     
     
         15 . The composition of  claim 13 , further comprising an antimicrobial agent. 
     
     
         16 . The composition of  claim 15 , wherein the antimicrobial agent is benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, centrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, exetidine, imidurea, phenol, phenoxyethanol, phenylethl alcohol, phenlymercuric nitrate, propylene glycol, or thimerosal. 
     
     
         17 . A method of treating a disease in a patient in need thereof comprising administering a composition of any one of  claims 1 - 16  to the patient, thereby treating the disease in the patient. 
     
     
         18 . The method of  claim 17 , wherein the disease is a cancer. 
     
     
         19 . The method of  claim 18 , wherein the therapeutic agent is an inhibitory RNA targeting an oncogene. 
     
     
         20 . The method of  claim 19 , wherein the inhibitory RNA targets Kras G12D . 
     
     
         21 . The method of  claim 18 , wherein the therapeutic agent is a tumor suppressor protein. 
     
     
         22 . The method of  claim 17 , further comprising administering at least a second therapy to the patient. 
     
     
         23 . The method of  claim 22 , wherein the second therapy comprises a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, or immunotherapy. 
     
     
         24 . The method of  claim 17 , wherein the patient is a human. 
     
     
         25 . A composition comprising a lipid-based nanoparticle and an excipient for use in the treatment of a disease in a patient, wherein the lipid-based nanoparticle comprises CD47 on its surface and wherein the lipid-based nanoparticle comprises a therapeutic agent. 
     
     
         26 . The composition of  claim 25 , wherein the disease is a cancer. 
     
     
         27 . The composition of  claim 26 , wherein the therapeutic agent is an inhibitory RNA targeting an oncogene. 
     
     
         28 . The composition of  claim 27 , wherein the inhibitory RNA targets Kras G12D . 
     
     
         29 . The composition of  claim 26 , wherein the therapeutic agent is a tumor suppressor protein. 
     
     
         30 . The composition of  claim 25 , wherein the composition is formulated for parenteral administration. 
     
     
         31 . The composition of  claim 30 , wherein the composition is formulated for intravenous, intramuscular, sub-cutaneous, or intraperitoneal injection. 
     
     
         32 . The composition of  claim 30 , further comprising an antimicrobial agent. 
     
     
         33 . The composition of  claim 32 , wherein the antimicrobial agent is benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, centrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, exetidine, imidurea, phenol, phenoxyethanol, phenylethl alcohol, phenlymercuric nitrate, propylene glycol, or thimerosal. 
     
     
         34 . The composition of  claim 25 , further comprising at least a second therapy. 
     
     
         35 . The composition of  claim 34 , wherein the second therapy comprises a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, or immunotherapy. 
     
     
         36 . The composition of  claim 25 , wherein the patient is a human. 
     
     
         37 . Use of a lipid-based nanoparticle in the manufacture of a medicament for the treatment of a disease, wherein the lipid-based nanoparticle comprises CD47 on its surface and wherein the lipid-based nanoparticle comprises a therapeutic agent. 
     
     
         38 . The use of  claim 37 , wherein the disease is a cancer. 
     
     
         39 . The use of  claim 38 , wherein the therapeutic agent is an inhibitory RNA targeting an oncogene. 
     
     
         40 . The use of  claim 39 , wherein the inhibitory RNA targets Kras G12D . 
     
     
         41 . The use of  claim 38 , wherein the therapeutic agent is a tumor suppressor protein. 
     
     
         42 . The use of  claim 37 , wherein the medicament is formulated for parenteral administration. 
     
     
         43 . The use of  claim 42 , wherein the medicament is formulated for intravenous, intramuscular, sub-cutaneous, or intraperitoneal injection. 
     
     
         44 . The use of  claim 37 , wherein the medicament comprises an antimicrobial agent. 
     
     
         45 . The use of  claim 44 , wherein the antimicrobial agent is benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, centrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, exetidine, imidurea, phenol, phenoxyethanol, phenylethl alcohol, phenlymercuric nitrate, propylene glycol, or thimerosal.

Join the waitlist — get patent alerts

Track US2018177727A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.